Vertex Pharma (VRTX) Tops Q1 EPS by 2c; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $524.52 --0%
EPS Growth %: -0.8%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: -0.8%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $3.05, $0.02 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Vertex Pharma reaffirms FY2023 revenue of $9.55-9.7 billion, versus the consensus of $9.7 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spotify (SPOT) Misses Q3 EPS by 36c; misses on guidance
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- TTM Technologies (TTMI) Tops Q3 EPS by 20c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
